ORGO
NASDAQ · Biotechnology
Organogenesis Holdings Inc
$2.39
-0.14 (-5.53%)
Open$2.16
Previous Close$2.53
Day High$2.46
Day Low$2.04
52W High$7.08
52W Low$2.21
Volume—
Avg Volume1.40M
Market Cap325.46M
P/E Ratio8.79
EPS$0.25
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+249.4% upside
Current
$2.39
$2.39
Target
$8.35
$8.35
$5.30
$8.35 avg
$10.56
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 589.85M | 547.37M | 163.70M |
| Net Income | 38.71M | 32.33M | 15.03M |
| Profit Margin | 6.6% | 6.2% | 9.2% |
| EBITDA | 62.70M | 55.27M | 20.76M |
| Free Cash Flow | — | — | 17.26M |
| Rev Growth | +7.8% | +7.8% | +17.3% |
| Debt/Equity | 0.05 | 0.05 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |